The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Open accessAbstract
Significance: Cancer immune evasion is well described. In some cases, this may be overcome by enhancing T-cell responses. We show that despite the presence of antitumor T cells, immunotherapeutic antibodies are ineffective in a murine pancreatic cancer model recapitulating the human disease. Removing the carcinoma-associated fibroblast (CAF) expressing fibroblast activation protein (FAP) from tumors permitted immune control of tumor growth and uncovered the efficacy of these immunotherapeutic antibodies. FAP + CAFs are the only tumoral source of chemokine (C-X-C motif) ligand 12 (CXCL12), and administering AMD3100, an inhibitor of chemokine (C-X-C motif) receptor 4, a CXCL12 receptor, also revealed the antitumor effects of an immunotherapeutic antibody and greatly diminished cancer cells. These findings may have wide clinical relevance because FAP + cells are found in almost all human adenocarcinomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“targeting CXCL12 signalling could be considered to be targeting CAFs as they are the major source of the chemokine in many tumours121.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“most studies have suggested an immunosuppressive role of CAFs121”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [121]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Interference with the action of CXCL12 produced by CAFs promotes T cell-mediated tumour control16,121,122”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [121]
In the citing paper
“the transcriptional profiles of apCAFs overlap with mesothelial cells150, and based on lineage tracing studies in mice have been postulated to derive from a mesothelial origin145”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [150]
In the citing paper
“They can further differentiate into myofibroblasts that express α-smooth muscle actin232.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [232]
In the citing paper
“fibroblast activation protein (FAP)+ CAFs inhibited anti-tumor function of T cells in gastric cancer and pancreatic cancer and targeting these FAP+ subtypes enhanced tumor response to ICB (Feig et al., 2013).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Feig et al., 2013
In the citing paper
“Moreover, CAF depletion using diphtheria toxin‐based immunotherapy reduced cancer growth by increasing CD8+ Teff‐cell infiltration to the TME [102].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [102]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Oura, K., Morishita, A., Tadokoro, T., Fujita, K., Tani, J., & Kobara, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413590 · Cited by 35
Pancreatic cancer: treatment approaches and trends
Pereira, N. P., & Corrêa, J. R. (2018) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2018.13 · Cited by 33
Alagpulinsa, D. A., Cao, J. J. L., Sobell, D., & Poznansky, M. C. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.011 · Cited by 33
From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer
Bazzichetto, C., Conciatori, F., Luchini, C., Simionato, F., Santoro, R., Vaccaro, V., Corbo, V., Falcone, I., Ferretti, G., Cognetti, F., et al. (2020) · Cells · doi:10.3390/cells9020309 · Cited by 32
Altered Tissue and Plasma Levels of Fibroblast Activation Protein-α (FAP) in Renal Tumours
Solano-Iturri, J. D., Errarte, P., Etxezarraga, C., Echevarrı́a, E., Angulo, J. C., Lopez, J. I., & Larrinaga, G. (2020) · Cancers · doi:10.3390/cancers12113393 · Cited by 33
Rong, X., Jin-yu, L., Liu, Y., Wang, Z., Zeng, D., Li, Y., Li, S., Wu, J., Shen, Z., Shi, M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.802257 · Cited by 34
Tsai, Y.-T., Li, C.-Y., Huang, Y., Chang, T., Lin, C., Chuang, C.-H., Wang, C., Anuraga, G., Chang, T.-H., Shih, T., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02309-7 · Cited by 33
Therapeutic poly(amino acid)s as drug carriers for cancer therapy
Hu, H., Zhang, Z., Fang, Y., Chen, L., & Wu, J. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.107953 · Cited by 33
Mutant P53 in the formation and progression of the tumor microenvironment: Friend or foe
Asl, E. R., Rostamzadeh, D., Duijf, P. H. G., Mafi, S., Mansoori, B., Barati, S., Cho, W. C. S., & Mansoori, B. (2023) · Life Sciences · doi:10.1016/j.lfs.2022.121361 · Cited by 38
Tumor-derived factors affecting immune cells
Russo, V. E. A., & Protti, M. P. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.005 · Cited by 33
Hwang, W. L., Jagadeesh, K. A., Guo, J. A., Hoffman, H. I., Yadollahpour, P., Mohan, R. R., Drokhlyansky, E., Wittenberghe, N. V., Ashenberg, O., Farhi, S. L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.25.267336 · Cited by 35
Hanley, C. J., & Thomas, G. J. (2021) · Oncotarget · doi:10.18632/oncotarget.27936 · Cited by 33
Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4
Hao, S., Xu, S., Li, L., Li, Y., Zhao, M., Chen, J., Zhu, S., Xie, Y., Jiang, H., Zhu, J., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-10165-7 · Cited by 32
Cancer‐associated fibroblasts: Is it a key to an intricate lock of tumorigenesis?
Aden, D., Zaheer, S., Ahluwalia, H., & Ranga, S. (2023) · Cell Biology International · doi:10.1002/cbin.12004 · Cited by 33
Fibroblast Activation Protein Inhibitor Theranostics
Mori, Y., Kratochwil, C., Haberkorn, U., & Giesel, F. L. (2023) · PET Clinics · doi:10.1016/j.cpet.2023.02.007 · Cited by 32
Ding, Z., Sun, S., Wang, X., Yang, X., Shi, W., Huang, X., Xie, S., Mo, F., Hou, X., Liu, A., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01507-4 · Cited by 32
Fibroblasts in Orchestrating Colorectal Tumorigenesis and Progression
Abudukelimu, S., de Miranda, N. F. C. C., & Hawinkels, L. J. A. C. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.01.013 · Cited by 34
Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma
Joseph, A. M., Aiyan, A. A., al-Ramadi, B. K., Singh, S. K., & Kishore, U. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1323198 · Cited by 36
Fu, Y., Guo, X., Sun, L., Cui, T., Wu, C., Wang, J., Liu, Y., & Liu, L. (2024) · eLife · doi:10.7554/elife.95009 · Cited by 31
Genetic polymorphisms associated with pancreatic cancer survival: a genome‐wide association study
Tang, H., Wei, P., Chang, P., Li, Y., Dong, Y., Liu, C., Hassan, M. M., & Li, D. (2017) · International Journal of Cancer · doi:10.1002/ijc.30762 · Cited by 30
Sun, Y., Wang, R., Qiao, M., Yan-chun, X., Guan, W., & Wang, L. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26433 · Cited by 32
Nguyen, H. H., Kim, M. B., Wilson, R. J., Butch, C. J., Kuo, K. M., Miller, E. J., Tahirovic, Y. A., Jēčs, E., Truax, V. M., Wang, T., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00450 · Cited by 32
Stress responses in stromal cells and tumor homeostasis
Vitale, I., Manic, G., Galassi, C., & Galluzzi, L. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.004 · Cited by 33
Facing the future: challenges and opportunities in adoptive T cell therapy in cancer
Magalhaes, I., Carvalho‐Queiroz, C., Hartana, C. A., Kaiser, A. M., Lukic, A., Mints, M., Nilsson, O., Grönlund, H., Mattsson, J., & Berglund, S. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1608179 · Cited by 31
Nair-Gupta, P., Rudnick, S. I., Luistro, L. L., Smith, M., McDaid, R., Li, Y., Pillarisetti, K., Joseph, J., Heidrich, B. J., Packman, K. E., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0331-4 · Cited by 32
CD36 and CD97 in Pancreatic Cancer versus Other Malignancies
Tănase, C., Gheorghișan-Gălățeanu, A.-A., Popescu, I. D., Mihai, S., Codrici, E., Albulescu, R., & Hinescu, M. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165656 · Cited by 32
Cho, C., Mukherjee, R., Peck, A. R., Sun, Y., McBrearty, N., Katlinski, K. V., Gui, J., Govindaraju, P. K., Puré, E., Rui, H., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01424-7 · Cited by 32
Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer
Ware, M. B., El‐Rayes, B. F., & Lesinski, G. B. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001100 · Cited by 32
Brennen, W. N., Thorek, D. L. J., Jiang, W., Krueger, T. E. G., Antony, L., Denmeade, S. R., & Isaacs, J. T. (2020) · Immunotherapy · doi:10.2217/imt-2020-0066 · Cited by 33
Yu, S., Lu, Y., Su, A., Chen, J., Li, J., Zhou, B., Liu, X., Xia, Q., Li, Y., Li, J., et al. (2021) · Advanced Science · doi:10.1002/advs.202101848 · Cited by 32
Self-citationChallenges and Future Perspectives of Immunotherapy in Pancreatic Cancer
Wandmacher, A. M., Letsch, A., & Sebens, S. (2021) · Cancers · doi:10.3390/cancers13164235 · Cited by 33
Sunami, Y., Häußler, J., Zourelidis, A. A., & Kleeff, J. H. (2022) · Cancers · doi:10.3390/cancers14030744 · Cited by 36
Seeber, A., Battaglin, F., Zimmer, K., Kocher, F., Baca, Y., Xiu, J., Spizzo, G., Novotny‐Diermayr, V., Rieder, D., Puccini, A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3018 · Cited by 31
Shinkawa, T., Ohuchida, K., & Nakamura, M. (2022) · Cancers · doi:10.3390/cancers14163994 · Cited by 32
Transforming growth factor‐β signalling in tumour resistance to the anti‐PD ‐(L)1 therapy: Updated
Mortezaee, K., & Majidpoor, J. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17666 · Cited by 32
Jackson, K. W., Christiansen, V. J., Yadav, V. R., Silasi‐Mansat, R., Lupu, F., Awasthi, V., Zhang, R. R., & McKee, P. A. (2015) · Neoplasia · doi:10.1016/j.neo.2014.11.002 · Cited by 32
Delitto, D., Perez, C., Han, S., Gonzalo, D. H., Pham, K., Knowlton, A. E., Graves, C. L., Behrns, K. E., Moldawer, L. L., Thomas, R. M., et al. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1760-y · Cited by 32
Advances in immunotherapy for pancreatic ductal adenocarcinoma
Miyazawa, M., Katsuda, M., Kawai, M., Hirono, S., Okada, K., Kitahata, Y., & Yamaue, H. (2021) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.944 · Cited by 32
Opportunities and challenges to engineer 3D models of tumor-adaptive immune interactions
Visalakshan, R. M., Lowrey, M. K., Sousa, M. G. C., Helms, H. R., Samiea, A., Schutt, C. E., Moreau, J. M., & Bertassoni, L. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1162905 · Cited by 32
Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities
Min, K. K. M., Ffrench, C. B., Jessup, C. F., Shepherdson, M., Barreto, S. G., & Bonder, C. S. (2023) · Cancers · doi:10.3390/cancers15082354 · Cited by 35
Portillo, A. L., Monteiro, J. K., Rojas, E. A. P., Ritchie, T. M., Gillgrass, A. E., & Ashkar, A. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1286750 · Cited by 32
Reid, S. E., Pantaleo, J., Bolívar, P., Bocci, M., Sjölund, J., Morsing, M., Cordero, E., Larsson, S., Malmberg, M., Seashore-Ludlow, B. A., et al. (2024) · Oncogene · doi:10.1038/s41388-024-02973-x · Cited by 30
Disruption of cellular plasticity by repeat RNAs in human pancreatic cancer
You, E., Danaher, P. J., Lu, C., Sun, S., Zou, L. S., Phillips, I. E., Rojas, A. S., Ho, N. I., Song, Y., Raabe, M. J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.09.024 · Cited by 31
Mellman, I., Hubbard-Lucey, V. M., Tontonoz, M. J., Kalos, M. D., Chen, D. S., Allison, J. P., Drake, C. G., Levitsky, H., Lönberg, N., van der Burg, S. H., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0045 · Cited by 31
Self-citationHan, X., Zhang, W.-H., Wang, W., Yu, X., & Liu, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188444 · Cited by 31
Hot or cold: Bioengineering immune contextures into in vitro patient-derived tumor models
Too, N. S. H., Ho, N. C. W., Adine, C., Iyer, N. G., & Fong, E. L. S. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.001 · Cited by 32
Site-Dependent Immune Escape Due to Impaired Dendritic Cell Cross-Priming
Diamond, M. S., Lin, J., & Vonderheide, R. H. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0785 · Cited by 30
Lin, Y.-N., Schmidt, M. O., Sharif, G. M., Vietsch, E. E., Kiliti, A. J., Barefoot, M. E., Riegel, A. T., & Wellstein, A. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2027136 · Cited by 31
Alcaraz, L. B., Mallavialle, A., Mollévi, C., Boissière‐Michot, F., Mansouri, H., Simony-Lafontaine, J., Laurent‐Matha, V., Chardès, T., Jacot, W., Turtoï, A., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34345 · Cited by 31
An overview of polyamine metabolism in pancreatic ductal adenocarcinoma
Phanstiel, O. (2017) · International Journal of Cancer · doi:10.1002/ijc.31155 · Cited by 31
Strategies to overcome myeloid cell induced immune suppression in the tumor microenvironment
Cao, J. H., Chow, L., & DOW, S. W. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1116016 · Cited by 34
Bao, G., Wang, Z., Liu, L., Zhang, B., Song, S., Wang, D., Cheng, S., Moon, E. S., Roesch, F., Zhao, J., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06704-y · Cited by 30
MyD88 and Its Inhibitors in Cancer: Prospects and Challenges
Song, J., Li, Y., Wu, K., Hu, Y., & Fang, L. (2024) · Biomolecules · doi:10.3390/biom14050562 · Cited by 31
Hsu, S., Chou, C., Lin, I., Chang, W., Kuo, I., & Chiu, C. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01633-7 · Cited by 34
Zhong, P., Nakata, K., Oyama, K., Higashijima, N., Sagara, A., Date, S., Luo, H., Hayashi, M., Kubo, A., Wu, C., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03060-5 · Cited by 36
Priming cancer cells for drug resistance: role of the fibroblast niche
Fang, W. B., Yao, M., & Cheng, N. (2014) · Frontiers in Biology · doi:10.1007/s11515-014-1300-8 · Cited by 31
Harel, E., Drake, P. M., Barfield, R. M., Lui, I., Farr-Jones, S., Veer, L. V., Gartner, Z. J., Green, E. M., Lourenço, A. L., Cheng, Y., et al. (2019) · Antibodies · doi:10.3390/antib8040054 · Cited by 30
Chaudary, N., Hill, R. P., Stulik, L., & Milosevic, M. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.03.031 · Cited by 30
Immunobiology of cancer-associated fibroblasts in the context of radiotherapy
Hellevik, T., Berzaghi, R., Lode, K., Islam, A., & Martínez-Zubiaurre, I. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03112-w · Cited by 32
Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies
Belli, C., Antonarelli, G., Repetto, M., Bielo, L. B., Crimini, E., & Curigliano, G. (2022) · Cancers · doi:10.3390/cancers14174278 · Cited by 31
Regulatory T Cells in Pancreatic Cancer: Of Mice and Men
Reyes, C. M., Demir, E., Çifcibaşı, K., Istvánffy, R., Friess, H., & Demir, İ. E. (2022) · Cancers · doi:10.3390/cancers14194582 · Cited by 33
Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance
Qin, Y., & Xu, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1053120 · Cited by 32
Deciphering cancer fibroblasts
Biffi, G., & Tuveson, D. A. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20182069 · Cited by 30
Self-citationInhibiting stromal Class I HDACs curbs pancreatic cancer progression
Liang, G., Oh, T. G., Hah, N., Tiriac, H., Shi, Y., Truitt, M., Antal, C. E., Atkins, A. R., Li, Y., Fraser, C. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42178-6 · Cited by 32
Hou, D., Zhang, N., Zhang, P., Li, X., Wu, J.-C., Lv, M.-Y., Wang, Z.-J., Hu, X., Liang, J.-X., Wang, H., et al. (2024) · 中国科学通报：英文版 · doi:10.1016/j.scib.2024.10.032 · Cited by 29
Mempel, T. R., & Marangoni, F. (2019) · Immunological Reviews · doi:10.1111/imr.12761 · Cited by 30
Molina, E. R., Chim, L. K., Salazar, M. C., Koons, G. L., Menegaz, B. A., Ruiz-Velasco, A., Lamhamedi-Cherradi, S.-E., Vetter, A. M., Satish, T., Cuglievan, B., et al. (2019) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.9b01068 · Cited by 29
Martínez‐Useros, J., Martin-Galan, M., & García‐Foncillas, J. (2021) · Cancers · doi:10.3390/cancers13020322 · Cited by 29
Heij, L. R., Tan, X., Kather, J. N., Niehues, J. M., Sivakumar, S., Heussen, N. M., van der Kroft, G., Damink, S. W. M. O., Lang, S. A., Aberle, M. R., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030490 · Cited by 29
Asiry, S., Kim, G., Filippou, P. S., Sanchez, L. R., Entenberg, D. R., Marks, D. K., Oktay, M. H., & Karagiannis, G. S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654877 · Cited by 29
Chen, Q., Wang, Q., Wang, Y., Chu, Y., Luo, Y., You, H., Su, B., Li, C., Guo, Q., Sun, T., et al. (2022) · Small · doi:10.1002/smll.202107712 · Cited by 29
Emerging concepts in designing next-generation multifunctional nanomedicine for cancer treatment
Chakraborty, K., Tripathi, A., Mishra, S., Mallick, A. M., & Roy, R. S. (2022) · Bioscience Reports · doi:10.1042/bsr20212051 · Cited by 30
Targeting Tumour-Associated Fibroblasts in Cancers
Shah, K., Mallik, S. B., Gupta, P. K., & Iyer, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.908156 · Cited by 31
Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy
Smith, C., Zheng, W., Dong, J., Wang, Y., Lai, J., Liu, X., & Yin, F. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i27.3297 · Cited by 29
Dong, Y., Zhou, H., Alhaskawi, A., Wang, Z., Lai, J., Yao, C., Liu, Z., Ezzi, S. H. A., Kota, V. G., Abdulla, M. H. A. H., et al. (2023) · Cancers · doi:10.3390/cancers15041193 · Cited by 29
Targeting anticancer immunity in oral cancer: Drugs, products, and nanoparticles
Qin, L., & Wu, J. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116751 · Cited by 29
Peng, S.-B., Horn, R. D. V., Yin, T., Brown, R. M., Roell, W. C., Obungu, V. H., Ruegg, C. E., Wroblewski, V. J., Raddad, E., & Stille, J. R. (2017) · Oncotarget · doi:10.18632/oncotarget.21816 · Cited by 29
Chen, Z., Zhuo, S., He, G., Tang, J., Hao, W., Gao, W., Yang, K., & Xu, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.721897 · Cited by 27
Nano-trapping CXCL13 reduces regulatory B cells in tumor microenvironment and inhibits tumor growth
Shen, L., Li, J., Liu, Q., Das, M., Song, W., Zhang, X., Tiruthani, K., Dorosheva, O., Hu, H., Lai, S. K., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.039 · Cited by 28
Bête Noire of Chemotherapy and Targeted Therapy: CAF-Mediated Resistance
De, P. K., Aske, J. C., Sulaiman, R. A., & Dey, N. (2022) · Cancers · doi:10.3390/cancers14061519 · Cited by 29
Ma, Y., Nikfarjam, M., & He, H. Z. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215868 · Cited by 28
Igniting Hope for Tumor Immunotherapy: Promoting the “Hot and Cold” Tumor Transition
Chen, W., Ma, Y., Wang, F., Liao, Y., Chen, Y., Zhao, B., Zhao, Q., Wang, D., & Tang, D. (2022) · Clinical Medicine Insights Oncology · doi:10.1177/11795549221120708 · Cited by 31
Self-citationThiery, J. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00103 · Cited by 29
Nishiwaki, N., Noma, K., Ohara, T., Kunitomo, T., Kawasaki, K., Akai, M., Kobayashi, T., Narusaka, T., Kashima, H., Sato, H., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03378-7 · Cited by 28
Targeting Transcriptional and Epigenetic Reprogramming in Stromal Cells in Fibrosis and CancerPreprint
Hah, N., Sherman, M. H., Yu, R. T., Downes, M., & Evans, R. M. (2015) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2015.80.027185 · Cited by 28
Xue, X., Wang, X., Pang, M., Yu, L., Qian, J., Li, X., Tian, M., Lu, C. Y., Xiao, C., & Liu, Y. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02452-1 · Cited by 29
Cancer‐Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets
Li, Y., Liu, Q., Jing, X., Wang, Y., Jia, X., Yang, X., & Chen, K. (2025) · MedComm · doi:10.1002/mco2.70292 · Cited by 32
Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors
Yan, L., & Liu, B. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s190336 · Cited by 27
Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer
Page, D. B., Bourla, A. B., Daniyan, A. F., Naidoo, J., Smith, E. L., Smith, M. M., Friedman, C. F., Khalil, D. N., Funt, S. A., Shoushtari, A. N., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0072-2 · Cited by 27
Deciphering the Role of Innate Immune NF-ĸB Pathway in Pancreatic Cancer
Khurana, N., Dodhiawala, P. B., Bulle, A. S., & Lim, K. (2020) · Cancers · doi:10.3390/cancers12092675 · Cited by 27
Garcia‐Vicién, G., Mezheyeuski, A., Bañuls, M., Ruiz-Roig, N., & Mollevı́, D. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041544 · Cited by 29
Stimulus-responsive gold nanotheranostic platforms for targeting the tumor microenvironment
Mandal, D., Paul, P., & Bhowmik, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821712-2.00003-7 · Cited by 27
Breast cancer immune microenvironment: from pre-clinical models to clinical therapies
Wilson, B. E., Gorrini, C., & Cescon, D. W. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06431-0 · Cited by 27
Cancer-associated fibroblasts and the tumor microenvironment in non-small cell lung cancer
Suzuki, J., Tsuboi, M., & Ishii, G. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2019018 · Cited by 22
Geng, F., Dong, L., Bao, X., Guo, Q., Guo, J., Zhou, Y., Yu, B., Wu, H., Wu, J., Zhang, H., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.07.008 · Cited by 27
Stromal circuits involving tumor-associated macrophages and cancer-associated fibroblasts
Timperi, E., & Romano, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1194642 · Cited by 29
Hazrati, A., Malekpour, K., Mirsanei, Z., Khosrojerdi, A., Rahmani-Kukia, N., Heidari, N., Abbasi, A., & Soudi, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1280601 · Cited by 27
Collagen remodeling-mediated signaling pathways and their impact on tumor therapy
Yuan, Z., Lin, B., Wang, C., Yan, Z., Yang, F., & Su, H. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108330 · Cited by 26
Pancreatic Cancer: Pathogenesis and Clinical Studies
Zhou, K., Liu, Y., Tang, C., & Zhu, H. (2025) · MedComm · doi:10.1002/mco2.70162 · Cited by 28
Plasticity and Functional Heterogeneity of Cancer-Associated Fibroblasts
Flynn, J. M., Thadani, N., Gallagher, E. E., Azzaro, I., Bodnar, C. M., McCarty, C. P., Romano, G., Webster, M. R., & Capparelli, C. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-3037 · Cited by 30
Metadata
- Authors
- Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., Teichmann, S. A., Janowitz, T., Jodrell, D. I., Tuveson, D. A., & Fearon, D. T.
- Affiliations
- University of Cambridge (GB)
- MRC Laboratory of Molecular Biology (GB)
- Johns Hopkins University (US)
- Ludwig Collaborative Laboratory, Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21231; and
- European Bioinformatics Institute (GB)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2013-11-25
- Volume
- 110
- Issue
- 50
- Pages
- 20212-20217
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3864274
- OpenAlex
- W2086834665
- Cited by
- 2,100
- References
- 28
- Citations by year
- 2026: 252 · 2025: 157 · 2024: 226 · 2023: 214 · 2022: 221 · 2021: 244 · 2020: 203 · 2019: 149 · 2018: 125 · 2017: 119 · 2016: 95 · 2015: 63 · 2014: 30
- FWCI
- 33.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Funders
- Wellcome Trust
- Cancer Research UK (15678)
- National Institute for Health and Care Research (CL-2011-14-007)
- Medical Research Council (MC_PC_12012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Keywords
- pancreatic ductal adenocarcinoma, CXCL12, fibroblast activation protein, cancer-associated fibroblasts, PD-L1 blockade, CTLA-4 blockade, tumor immune evasion, tumor stroma, CXCR4 inhibition, AMD3100, CD8+ T cells, chemokine signaling, immunotherapy resistance
- MeSH terms
- Cyclams, Fibroblast Activation Protein Alpha, Analysis of Variance, Animals, Base Sequence, Benzylamines, Fibroblasts, Flow Cytometry, Fluorescent Antibody Technique, Heterocyclic Compounds, Immunohistochemistry, Immunotherapy, Membrane Proteins, Molecular Sequence Data, Pancreatic Neoplasms, Endopeptidases, Serine Endopeptidases, Sequence Analysis, RNA, Gelatinases, Tumor Escape, Carcinoma, Pancreatic Ductal, Mice, Chemokine CXCL12, Enzyme-Linked Immunospot Assay
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
